No Data
No Data
12 Health Care Stocks Moving In Thursday's After-Market Session
AN2 Therapeutics Faces Setback in Phase 3 Study
AN2 Therapeutics Reports Phase 3 Portion Of Previously Terminated EBO-301 Study Data; Outlines Future Milestones From Boron Chemistry Pipeline
Express News | AN2 Therapeutics Inc - Extends Cash Runway Into 2028
Express News | AN2 Therapeutics Inc - Topline Data for Melioidosis Trial Expected in 2Q25
Express News | AN2 Therapeutics Inc - Ebo-301 Phase 3 Study Misses Primary Endpoint in Mac Lung Disease